Macquarie Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Macquarie Group’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-180,000	Closed	-$2.77M	–	1407
2025 Q3	$2.77M	Hold	180,000	–	–	﹤0.01%	1085
2025 Q2	$1.69M	Hold	180,000	–	–	﹤0.01%	1269
2025 Q1	$2.21M	Hold	180,000	–	–	﹤0.01%	1187
2024 Q4	$2.38M	Sell	180,000 -63,352	-26%	-$1.08M	﹤0.01%	1149
2024 Q3	$4.68M	Buy	243,352 +433	+0.2%	+$8.95K	0.01%	976
2024 Q2	$4.99M	Sell	242,919 -73	-0%	-$1.53K	0.01%	973
2024 Q1	$5.78M	Sell	242,992 -1,098	-0.4%	-$24.5K	0.01%	926
2023 Q4	$5.28M	Buy	244,090 +11,624	+5%	+$179K	0.01%	953
2023 Q3	$3.38M	Buy	232,466 +1,023	+0.4%	+$19.4K	﹤0.01%	1023
2023 Q2	$4.84M	Buy	231,443 +51,443	+29%	+$1.07M	0.01%	937
2023 Q1	$3.8M	Hold	180,000	–	–	﹤0.01%	985
2022 Q4	$4.58M	Hold	180,000	–	–	0.01%	998
2022 Q3	$4.35M	Sell	180,000 -991	-0.5%	-$22.2K	0.01%	1018
2022 Q2	$3.48M	Hold	180,991	–	–	﹤0.01%	1131
2022 Q1	$3.15M	Hold	180,991	–	–	﹤0.01%	1243
2021 Q4	$3.96M	Hold	180,991	–	–	﹤0.01%	1177
2021 Q3	$3.46M	Hold	180,991	–	–	﹤0.01%	1207
2021 Q2	$3.11M	Hold	180,991	–	–	﹤0.01%	1279
2021 Q1	$4.05M	Buy	180,991 +991	+0.6%	+$22.4K	0.01%	964
2020 Q4	$4M	Hold	180,000	–	–	0.01%	923
2020 Q3	$2.66M	Hold	180,000	–	–	﹤0.01%	967
2020 Q2	$2.67M	Hold	180,000	–	–	﹤0.01%	930
2020 Q1	$1.98M	Hold	180,000	–	–	﹤0.01%	913
2019 Q4	$1.58M	Hold	180,000	–	–	﹤0.01%	1104
2019 Q3	$1.34M	Hold	180,000	–	–	﹤0.01%	1137
2019 Q2	$1.68M	Hold	180,000	–	–	﹤0.01%	1066
2019 Q1	$945K	Hold	180,000	–	–	﹤0.01%	1206
2018 Q4	$801K	Hold	180,000	–	–	﹤0.01%	1209
2018 Q3	$1.45M	Hold	180,000	–	–	﹤0.01%	1110
2018 Q2	$1.26M	Buy	+180,000	New	+$1.77M	﹤0.01%	1123
2018 Q1	–	Sell	-1,200	Closed	-$11K	–	2343
2017 Q4	$11K	Buy	+1,200	New	+$11.9K	﹤0.01%	2252

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Macquarie Group's SNDX Position: Q4 2025 in Review

Macquarie Group sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 180,000 shares — an estimated $2.77M sold.

Macquarie Group first reported a position in SNDX in Q4 2017 and held it in 31 quarters. The position peaked at $5.78M in Q1 2024. 230 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

Macquarie Group reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Macquarie Group sold 180,000 Syndax Pharmaceuticals shares in Q4 2025, an estimated $2.77M.
Macquarie Group first reported a position in Syndax Pharmaceuticals in Q4 2017 and held it in 31 quarters.
Macquarie Group's Syndax Pharmaceuticals position peaked at $5.78M in Q1 2024.
230 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.